There is certainly a lot to like, the company reports are very...

There is certainly a lot to like, the company reports are very detailed and I agree with some other posters that they seem very transparent and give good regular updates to the market...

Directors Interest (all topped up recently) is good:
- Jane Bell 346,454 (direct) + 1,456,678 (Super) = 1,803,123 units = $324,564 (@ 18c)
-Dr Chris Burns: 2,527,798 units = $455,003 (@ 18c)
-Dr Robert Peach: 331,808 (Trust) + 1,332,952 (Company) = 1,664,760 units = $299,657
-Dr. John Lambert: 162,500 (direct) + 220,000 (indirect) = 382,500 units = $68,850
-Dr. Warwick Tong: 2,355,140 + 500,000 = 2,855,140 units =$513,925

Regarding the science & drug:
- long-term stability testing data has shown that AMP945 can be stored for periods of more than 24 months without detectable deterioration
- drug can be administered orally
- Origins in Cancer Therapeutics Cooperative Research Centre
- Clear differentiation from other FAK inhibitors in development
- AMP945 improves survival in an aggressive pancreatic cancer Model 25% improvement in survival when added to standard of care
- Phase 1 trial was safe and well-tolerated at all doses tested and there was a low risk of interaction with other drugs in combination therapy
- awarded Orphan Drug Designation

TAM in the B's


There is a few options floating around though, what's that about 13% dilution


Two phase 2s beginning soon:
The Phase 2 clinical trial of AMP945 in patients with pancreatic cancer remains on track to commence during the current quarter. In addition, the extended (3-month) toxicology studies required to support the Phase 2 clinical trial of AMP945 in patients with fibrotic lung disease are on schedule to commence in February 2022 as previously advised.


In the above graphic it seems they wont report early results until Q2 2023, but when you look at their investor presentations for 2022, they mention they will report early results... So it is possible they can report something this year on efficacy for either trial?




If not, are there enough inflection points this year to keep investors interested and turn around this downwards trend?

The only thing I can think of, and seems very plausible from their reports, is if they can land a deal like the ones below:



Some of these company's are preclinical and have deals, so Big Pharma is obviously willing to eat up good opportunities. Given that safety has been proven, do they really need to see efficacy before commit? Any of of those deals would have the SP in multiples of where it is today...

I don't understand why the market is valuing this company at 35m, given outstanding safety and on the cusp of starting to Ph2s, 100m isn't that unreasonable... Perhaps it is because timelines to get results are too long and there is nothing to see here in the meantime?

Picked up a small parcel today. Interested to learn more